Dr. Reddy's To Resume Semaglutide Supply By November Targeting 6–7 Million Pens

Market snapshot: Dr. Reddy's Laboratories has laid out a clear recovery timeline for its blockbuster generic semaglutide portfolio, targeting supply resumption by November 2026 with a revised output of 6 million to 7 million pens. Despite near-term earnings absorption from a ₹240 crore API inventory write-down in Q1 FY27, management maintains a solid EBITDA margin guidance in the neighborhood of 20% for the next quarter. Long-term innovation continues with a guided R&D spending framework of 7% to 8% of revenues, mostly concentrated on assets commercializing post-2034.

Data Snapshot

• Q1 FY27 consolidated revenue from operations stood at ₹8,070.5 crore, down 5.6% year-over-year, heavily impacted by the erosion of lenalidomide revenues.
• Reported EBITDA for Q1 FY27 came in at ₹1,008.8 crore with a margin of 12.5%, compressed by a ₹240 crore inventory and associated costs provision tied to semaglutide API issues.
• Excluding the semaglutide-related inventory impact, Dr. Reddy's underlying Q1 FY27 EBITDA margin was 15.4% and reported return on capital employed was 8% compared to the reported 5.3%.

What's Changed

• The semaglutide supply timeline has shifted from immediate commercial launch scaling to a temporary hold, with shipments slated to restart by November 2026.
• The FY27 semaglutide sales target has been revised downwards to 6 million to 7 million pens, from the company's initial first-year target of 12 million pens.
• Consolidated net profit crashed 68.7% year-over-year to ₹443.5 crore, reflecting the high base of lenalidomide revenues in the prior year and the unexpected semaglutide provision.

Key Takeaways

• The semaglutide API impurity snag identified during scale-up is a technical validation issue rather than a structural drug product safety concern, requiring no commercial product recall.
• While the short-term disruption impacts Q2 volumes, it does not alter Dr. Reddy's existing global regulatory submissions or approvals in pipeline markets like Brazil, Turkey, and Mexico.
• Underlying double-digit base business growth persists across key regions, keeping the long-term strategic trajectory of the pharmaceutical major intact.

SAHI Perspective

The validation hurdle in scaling complex peptide synthetics like semaglutide highlights the technical barriers of the GLP-1 generic landscape. While the short-term volume revision is disappointing, Dr. Reddy's rapid identification of the issue and transparent adjustment of targets protect its brand equity. Crucially, a robust cash surplus of ₹3,058 crore provides the financial shield to absorb these transient bottleneck costs without derailing its long-term research pipeline.

Market Implications

The temporary supply gap through October 2026 creates a tactical opening for domestic competitors like Sun Pharma and Zydus to secure early market share in India's generic GLP-1 segment. However, Dr. Reddy's first-mover status in Canada and deep manufacturing alignment with contract partner OneSource Specialty Pharma suggest it remains well-positioned to recapture structural volumes once supplies normalize in late autumn.

Trading Signals

Market Bias: Bearish

Short-term pressure remains elevated following a 68.7% YoY decline in Q1 FY27 PAT to ₹443.5 crore. The 3-to-4 month delay in scaling high-margin semaglutide volumes caps immediate financial catalysts, although a normalized next-quarter margin floor of ~20% limits downside.

Underweight: Pharmaceuticals (Near-term execution and scale-up bottlenecks)

Trigger Factors:

• Completion of the semaglutide API remedial testing batches by the third week of September 2026
• Resumption of API supply to manufacturing partner OneSource in October 2026
• EBITDA margin recovery back to the guided 20% floor in Q2 FY27

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian anti-obesity and diabetes therapy landscape is undergoing structural pricing and volume shifts following the patent expiry of semaglutide in March 2026. While over 50 domestic players are evaluating entry into this high-growth peptide segment, Dr. Reddy's scale-up experience demonstrates that complex generic manufacturing compliance and API quality control are the true differentiators over simple price competition.

Key Risks to Watch

• Process adjustments or validation testing failures extending the semaglutide manufacturing halt beyond November 2026.
• Accelerated market share capture by rival generic drugmakers during Dr. Reddy's supply absence in India and Canada.
• Persistently elevated freight and raw solvent costs driven by ongoing geopolitical tensions in the Middle East.

Recent Developments

In July 2026, Dr. Reddy's Laboratories reported a 68.7% year-over-year plunge in consolidated net profit to ₹443.5 crore, missing street estimates. Prior to this, the company had successfully launched its generic semaglutide injection in Canada on May 15, 2026, following a landmark Notice of Compliance approval from Health Canada on April 28, 2026.

Closing Insight

While Dr. Reddy's Q1 FY27 performance was overshadowed by temporary peptide manufacturing snags and the natural roll-off of lenalidomide, the company's financial core remains intact. The maintained EBITDA floor of 20% and strategic alignment towards post-2034 assets point to a business that is trading near its valuation trough, with key catalysts slated for late fiscal 2027.

High Performance Trading with SAHI.